A client exposed to anthrax has presented to the healthcare setting. Which of the following medications below is the treatment for this biological exposure?
Amoxicillin/clavulanate (Augmentin)
Nystatin (Mycostatin)
Ciprofloxacin (Cipro)
Tamoxifen
The Correct Answer is C
A. Amoxicillin/clavulanate (Augmentin): Amoxicillin/clavulanate is a broad-spectrum antibiotic but not the preferred choice for anthrax exposure.
B. Nystatin (Mycostatin): Nystatin is an antifungal medication used for treating fungal infections, such as oral thrush or cutaneous candidiasis. It is not effective against anthrax, which is a bacterial infection.
C. Ciprofloxacin (Cipro): Ciprofloxacin, a fluoroquinolone, is the recommended first-line antibiotic for treating anthrax exposure due to its efficacy against Bacillus anthracis, the bacteria causing anthrax.
D. Tamoxifen: Tamoxifen is a selective estrogen receptor modulator (SERM) used primarily in the treatment of breast cancer. It has no role in treating bacterial infections like anthrax.
Free Nursing Test Bank
- Free Pharmacology Quiz 1
- Free Medical-Surgical Quiz 2
- Free Fundamentals Quiz 3
- Free Maternal-Newborn Quiz 4
- Free Anatomy and Physiology Quiz 5
- Free Obstetrics and Pediatrics Quiz 6
- Free Fluid and Electrolytes Quiz 7
- Free Community Health Quiz 8
- Free Promoting Health across the Lifespan Quiz 9
- Free Multidimensional Care Quiz 10
View Related questions
Correct Answer is B
Explanation
A. Thromboembolic events: This is not a black box warning for ciprofloxacin.
B. This drug has a black box warning for causing tendon rupture: Ciprofloxacin, a fluoroquinolone, has a black box warning for the risk of tendonitis and tendon rupture, especially in older adults or those on corticosteroids.
C. Endometrial cancers: Ciprofloxacin is not associated with cancer.
D. Breast cancer: There is no link between ciprofloxacin and breast cancer.
Correct Answer is D
Explanation
A. Tendon rupture: Tendon rupture is not a side effect associated with estrogen blockers.
B. Phlebitis: While thromboembolic events are a risk, phlebitis (inflammation of a vein) is not a typical concern.
C. Increased risk of lymphomas: Estrogen blockers are not known to increase the risk of lymphomas.
D. Thromboembolic events: Estrogen blockers, such as tamoxifen, are associated with an increased risk of thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism).